| Not Yet Recruiting | FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma NCT07446777 | University of Miami | N/A |
| Completed | A Real-world Study in Participants With Smoldering Multiple Myeloma NCT06472778 | Janssen-Cilag Ltd. | — |
| Recruiting | Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma NCT06183489 | Stichting European Myeloma Network | Phase 2 |
| Recruiting | Screening for AL Amyloidosis in Smoldering Multiple Myeloma NCT06365060 | Tufts Medical Center | — |
| Recruiting | Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial NCT06212323 | University of Utah | — |
| Recruiting | Whole Body MRI in Oncology NCT06895291 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Recruiting | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma NCT05597345 | University of Rochester | Phase 2 |
| Active Not Recruiting | Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program NCT05831358 | Case Comprehensive Cancer Center | N/A |
| Recruiting | The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple My NCT05841550 | Oslo University Hospital | Phase 1 / Phase 2 |
| Recruiting | Promoting Diagnosis and Management of AL in Italy (ProDigALIty) NCT06383143 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Active Not Recruiting | CAR- PRISM (PRecision Intervention Smoldering Myeloma) NCT05767359 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | European Myeloma Network (EMN) Sample Project NCT06237803 | European Myeloma Network B.V. | — |
| Recruiting | A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Unde NCT05640843 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) NCT05469893 | Irene Ghobrial, MD | Phase 2 |
| Recruiting | Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor C NCT05361694 | University of Miami | — |
| Recruiting | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH NCT05283993 | Peking University First Hospital | — |
| Active Not Recruiting | A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smol NCT04920084 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma NCT04850846 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey NCT04727294 | HealthTree Foundation | — |
| Completed | Screening to Improve Survival in AL Amyloidosis NCT04615572 | Tufts Medical Center | — |
| Active Not Recruiting | Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendat NCT04144387 | Intergroupe Francophone du Myelome | N/A |
| Enrolling By Invitation | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) NCT03815279 | Landspitali University Hospital | Phase 2 |
| Completed | Denosumab for Smoldering Multiple Myeloma NCT03839459 | University of Rochester | Phase 2 |
| Terminated | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma NCT03850522 | Lene Meldgaard Knudsen | Phase 2 |
| Active Not Recruiting | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant NCT03289299 | International Myeloma Foundation | Phase 2 |
| Recruiting | Registry for Adults With Plasma Cell Disorders (PCD's) NCT03717844 | UNC Lineberger Comprehensive Cancer Center | — |
| Active Not Recruiting | Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multip NCT03236428 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multipl NCT03301220 | Janssen Research & Development, LLC | Phase 3 |
| Active Not Recruiting | A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM NCT02886065 | Massachusetts General Hospital | Phase 1 |
| Completed | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma NCT02903381 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma NCT02916771 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma NCT02415413 | PETHEMA Foundation | Phase 2 |
| Completed | E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma NCT02279394 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Ou NCT02269592 | Dana-Farber Cancer Institute | — |
| Completed | Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma NCT01955395 | Dana-Farber Cancer Institute | N/A |
| Terminated | A Phase II Study of BI-505 in Smoldering Multiple Myeloma NCT01838369 | BioInvent International AB | Phase 2 |
| Completed | Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma NCT01718899 | OncoPep, Inc. | Phase 1 |
| Withdrawn | Imaging Studies and the Development of Multiple Myeloma NCT01571726 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma NCT01441973 | Bristol-Myers Squibb | Phase 2 |
| Completed | Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma NCT01302886 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma NCT01169337 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma NCT01248455 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imaging in MGUS, SMM and MM NCT01237054 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myel NCT01222286 | Innate Pharma | Phase 2 |
| Active Not Recruiting | Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders NCT01177527 | Dana-Farber Cancer Institute | — |
| Terminated | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) NCT00899353 | Marshall University | Phase 2 |
| Withdrawn | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma NCT00503763 | Meir Medical Center | Phase 2 |
| Active Not Recruiting | Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant NCT00114101 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous St NCT00112827 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma NCT00099047 | National Cancer Institute (NCI) | Phase 2 |